DK1441735T3 - N-substituerede hydroxypyrimidinon-carboxamid-inhibitorer af HIV-integrase - Google Patents
N-substituerede hydroxypyrimidinon-carboxamid-inhibitorer af HIV-integraseInfo
- Publication number
- DK1441735T3 DK1441735T3 DK02801950T DK02801950T DK1441735T3 DK 1441735 T3 DK1441735 T3 DK 1441735T3 DK 02801950 T DK02801950 T DK 02801950T DK 02801950 T DK02801950 T DK 02801950T DK 1441735 T3 DK1441735 T3 DK 1441735T3
- Authority
- DK
- Denmark
- Prior art keywords
- hiv
- compounds
- inhibitors
- aids
- hiv integrase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33956801P | 2001-10-26 | 2001-10-26 | |
US36219102P | 2002-03-06 | 2002-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1441735T3 true DK1441735T3 (da) | 2006-06-12 |
Family
ID=26991691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02801950T DK1441735T3 (da) | 2001-10-26 | 2002-10-21 | N-substituerede hydroxypyrimidinon-carboxamid-inhibitorer af HIV-integrase |
Country Status (35)
Country | Link |
---|---|
US (5) | US7169780B2 (xx) |
EP (1) | EP1441735B1 (xx) |
JP (1) | JP3927175B2 (xx) |
KR (1) | KR100862879B1 (xx) |
CN (3) | CN1700918B (xx) |
AT (1) | ATE318140T1 (xx) |
BR (1) | BRPI0213522C1 (xx) |
CA (1) | CA2463976C (xx) |
CO (1) | CO5580777A2 (xx) |
CY (1) | CY2008008I1 (xx) |
DE (3) | DE122009000048I1 (xx) |
DK (1) | DK1441735T3 (xx) |
EA (1) | EA007060B1 (xx) |
ES (1) | ES2258668T3 (xx) |
FR (1) | FR08C0026I2 (xx) |
GE (1) | GEP20063848B (xx) |
HK (1) | HK1085665A1 (xx) |
HR (1) | HRP20040373B1 (xx) |
HU (2) | HU230248B1 (xx) |
IL (2) | IL161337A0 (xx) |
IS (1) | IS2436B (xx) |
LT (1) | LTC1441735I2 (xx) |
LU (1) | LU91428I2 (xx) |
ME (1) | ME00427B (xx) |
MX (1) | MXPA04003932A (xx) |
NL (1) | NL300340I2 (xx) |
NO (3) | NO325206B1 (xx) |
NZ (1) | NZ533057A (xx) |
PL (1) | PL212914B1 (xx) |
PT (1) | PT1441735E (xx) |
RS (1) | RS51542B (xx) |
SI (1) | SI1441735T1 (xx) |
UA (1) | UA77454C2 (xx) |
WO (1) | WO2003035077A1 (xx) |
ZA (1) | ZA200402796B (xx) |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE345129T1 (de) | 2000-10-12 | 2006-12-15 | Merck & Co Inc | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
CZ20031028A3 (cs) | 2000-10-12 | 2003-08-13 | Merck & Co., Inc. | Aza- a polyazanaftalenylkarboxamidy |
JP4287649B2 (ja) | 2000-10-12 | 2009-07-01 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類 |
US20040229909A1 (en) | 2001-08-10 | 2004-11-18 | Ryuichi Kiyama | Antiviral agent |
AR036256A1 (es) | 2001-08-17 | 2004-08-25 | Merck & Co Inc | Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento |
JP3927175B2 (ja) * | 2001-10-26 | 2007-06-06 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | N−置換ヒドロキシピリミジノンカルボキサミド系hivインテグラーゼ阻害薬 |
CA2463975A1 (en) * | 2001-10-26 | 2003-05-01 | Maria Emilia Di Francesco | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
WO2003077857A2 (en) | 2002-03-15 | 2003-09-25 | Merck & Co., Inc. | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors |
WO2003094839A2 (en) * | 2002-05-09 | 2003-11-20 | Cytokinetics, Inc. | Pyrimidinone compounds, compositions and methods |
WO2003099211A2 (en) * | 2002-05-23 | 2003-12-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
WO2004004657A2 (en) | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
EP1549315A4 (en) * | 2002-09-11 | 2007-05-23 | Merck & Co Inc | DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS |
CA2498566A1 (en) * | 2002-09-11 | 2004-06-10 | Merck & Co., Inc. | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors |
KR20050087865A (ko) * | 2002-12-27 | 2005-08-31 | 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. | HIV 인테그라제 억제제로서 유용한테트라하이드로-4H-피리도[1,2-a]피리미딘 및 관련화합물 |
WO2004062613A2 (en) * | 2003-01-13 | 2004-07-29 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
US7037908B2 (en) | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
JP2007509149A (ja) * | 2003-10-20 | 2007-04-12 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬として有用なヒドロキシピリドピロロピラジンジオン化合物 |
US20050090668A1 (en) * | 2003-10-28 | 2005-04-28 | Dreher Spencer D. | Preparation of 5-hydroxy-6-oxo-1,6-dihydropyrimidine compounds |
AR046938A1 (es) * | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
JP2007518711A (ja) | 2003-12-19 | 2007-07-12 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害剤 |
TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
AU2005206511A1 (en) * | 2004-01-12 | 2005-08-04 | Gilead Sciences, Inc. | Pyrimidyl phosphonate antiviral compounds and methods of use |
CN1929737A (zh) | 2004-03-09 | 2007-03-14 | 默克公司 | Hiv整合酶抑制剂 |
WO2005087768A1 (en) * | 2004-03-09 | 2005-09-22 | Merck & Co., Inc. | Hiv integrase inhibitors |
EP1725535A4 (en) | 2004-03-09 | 2009-11-25 | Merck & Co Inc | HIV integrase |
JP2007528379A (ja) | 2004-03-09 | 2007-10-11 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | Hivインテグラーゼ阻害薬 |
EP1756114B1 (en) * | 2004-05-07 | 2014-11-19 | Merck Sharp & Dohme Corp. | Hiv integrase inhibitors |
US7273859B2 (en) * | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
US7115601B2 (en) | 2004-05-18 | 2006-10-03 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US7157447B2 (en) | 2004-05-28 | 2007-01-02 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
US7173022B2 (en) | 2004-05-28 | 2007-02-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
US7192948B2 (en) | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
WO2005120516A2 (en) | 2004-06-09 | 2005-12-22 | Merck & Co., Inc. | Hiv integrase inhibitors |
UA87884C2 (uk) * | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
EP1824957A4 (en) * | 2004-12-03 | 2011-02-09 | Merck Sharp & Dohme | USE OF ATAZANAVIR TO IMPROVE THE PHARMACOKINETIC PROPERTIES OF METABOLIZED MEDICINES BY UGT1A1 |
EP2586444B1 (en) * | 2004-12-03 | 2019-09-25 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate control composition |
ES2727577T3 (es) | 2004-12-03 | 2019-10-17 | Merck Sharp & Dohme | Composición farmacéutica que contiene un agente antinucleante |
AU2006228278C1 (en) * | 2005-03-31 | 2011-06-23 | Msd Italia S.R.L. | HIV integrase inhibitors |
LT3372281T (lt) | 2005-04-28 | 2021-12-10 | Viiv Healthcare Company | Policiklinis karbamoilpiridono darinys, turintis živ integrazės inhibitorinį aktyvumą |
WO2006121831A2 (en) * | 2005-05-10 | 2006-11-16 | Merck & Co., Inc. | Hiv integrase inhibitors |
EP1906971A2 (en) * | 2005-07-27 | 2008-04-09 | Gilead Sciences, Inc. | Antiviral compounds |
US7939537B2 (en) * | 2005-10-04 | 2011-05-10 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HIV integrase inhibitors |
EP1942736A2 (en) * | 2005-10-27 | 2008-07-16 | Merck & Co., Inc. | Hiv integrase inhibitors |
US20070129379A1 (en) * | 2005-12-01 | 2007-06-07 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
WO2007087188A2 (en) * | 2006-01-20 | 2007-08-02 | Merck & Co., Inc. | Taste-masked tablets and granules |
EP2044068A4 (en) * | 2006-07-17 | 2010-07-21 | Merck Sharp & Dohme | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS |
JP2009543865A (ja) | 2006-07-19 | 2009-12-10 | ユニバーシティ オブ ジョージア リサーチ ファウンデーション, インコーポレーテッド | ピリジノンジケト酸:併用療法におけるhiv複製の阻害剤 |
JP2010506913A (ja) * | 2006-10-18 | 2010-03-04 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害剤 |
CN101206209B (zh) * | 2006-12-19 | 2011-08-10 | 北京德众万全药物技术开发有限公司 | 一种用hplc法分析西多福韦原料及其制剂的方法 |
US7763630B2 (en) | 2007-06-06 | 2010-07-27 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
ATE499927T1 (de) * | 2007-06-22 | 2011-03-15 | Bristol Myers Squibb Co | Tablettierte atazanavirhaltige zusammensetzungen |
US7687509B2 (en) * | 2007-07-09 | 2010-03-30 | Concert Pharmaceuticals Inc. | Pyrimidinecarboxamide derivatives |
JP2011517313A (ja) | 2007-12-11 | 2011-06-02 | ビアメト ファーマシューティカルズ,インク. | 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤 |
BRPI0821349A2 (pt) | 2007-12-21 | 2019-09-24 | Hoffmann La Roche | compostos antivirais heterocíclicos |
AU2008346833B2 (en) * | 2008-01-08 | 2014-07-17 | Merck Sharp & Dohme Corp. | Process for preparing N-substituted hydroxypyrimidinone carboxamides |
EP2247601B1 (en) * | 2008-07-02 | 2013-04-10 | Avexa Limited | Thiazopyrimidinones and uses thereof |
JP4880097B1 (ja) * | 2008-10-06 | 2012-02-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Hivインテグラーゼ阻害剤 |
US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
WO2010140156A2 (en) | 2009-06-02 | 2010-12-09 | Hetero Research Foundation | Novel polymorphs of raltegravir potassium |
CN102471316B (zh) * | 2009-07-06 | 2013-12-11 | 先正达参股股份有限公司 | 杀虫化合物 |
WO2011024192A2 (en) | 2009-07-27 | 2011-03-03 | Matrix Laboratories Ltd | Novel polymorphs of raltegravir |
US8383639B2 (en) | 2009-10-15 | 2013-02-26 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
BR112012009857A8 (pt) | 2009-10-26 | 2023-04-11 | Merck Sharp & Dohme | Composições farmacêuticas sólidas contendo um inibidor de integrase |
DE102009056636A1 (de) | 2009-12-02 | 2011-06-09 | Ratiopharm Gmbh | Raltegravir-Polymorphe |
US8283366B2 (en) | 2010-01-22 | 2012-10-09 | Ambrilia Biopharma, Inc. | Derivatives of pyridoxine for inhibiting HIV integrase |
US9309199B2 (en) | 2010-03-04 | 2016-04-12 | Merck Sharp & Dohme Corp. | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders |
US9260413B2 (en) | 2010-03-04 | 2016-02-16 | Merck Sharp & Dohme Corp. | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders |
US9024032B2 (en) * | 2010-03-04 | 2015-05-05 | Merck Sharp & Dohme Corp. | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders |
MX336711B (es) * | 2010-03-04 | 2016-01-28 | Merck Sharp & Dohme | Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos. |
ES2524380T3 (es) | 2010-04-01 | 2014-12-05 | Teva Pharmaceutical Industries Ltd. | Sales de raltegravir y formas cristalinas de las mismas |
CA2999435A1 (en) * | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
WO2011127244A2 (en) | 2010-04-09 | 2011-10-13 | Bristol-Myers Squibb Company | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT |
US8962833B2 (en) | 2010-05-25 | 2015-02-24 | Hetero Research Foundation | Salts of raltegravir |
WO2012009446A1 (en) | 2010-07-16 | 2012-01-19 | Concert Pharmaceuticals Inc. | Novel pyrimidinecarboxamide derivatives |
CN101914067B (zh) * | 2010-08-26 | 2012-07-11 | 陈岱岭 | N-甲基嘧啶酮的合成方法 |
WO2012103105A1 (en) | 2011-01-24 | 2012-08-02 | Assia Chemical Industries Ltd. | Processes for preparing raltegravir and intermediates in the processes |
WO2012137142A1 (en) | 2011-04-06 | 2012-10-11 | Lupin Limited | Novel salts of raltegravir |
US9968607B2 (en) | 2011-04-25 | 2018-05-15 | Hetero Research Foundation | Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof |
EP2522665A1 (en) * | 2011-05-03 | 2012-11-14 | Sandoz Ag | Crystalline sodium salt of an HIV integrase inhibitor |
ES2450944T3 (es) | 2011-06-01 | 2014-03-25 | Ratiopharm Gmbh | Composición y comprimido que comprenden raltegravir |
CN103130787B (zh) * | 2011-11-24 | 2015-06-10 | 南开大学 | 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性 |
CN103130788B (zh) * | 2011-11-24 | 2015-09-02 | 南开大学 | 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性 |
BR112014013224B1 (pt) | 2011-11-30 | 2023-03-07 | Emory University | Inibidores de jak antivirais úteis no tratamento ou prevenção de infecções retrovirais e outras infecções virais |
WO2013098854A2 (en) * | 2011-12-26 | 2013-07-04 | Emcure Pharmaceuticals Limited | Synthesis of raltegravir |
BR112014018247A8 (pt) | 2012-01-25 | 2017-07-11 | Lupin Ltd | Pré-mistura de potássio de raltegravir amorfa e estável; processo; formulação farmacêutica; e método |
EP2875024A4 (en) * | 2012-07-20 | 2015-12-23 | Merck Sharp & Dohme | HIV TREATMENT WITH AMIDOSUBSTITUTED PYRIMIDINONE DERIVATIVES |
WO2014023691A1 (en) * | 2012-08-06 | 2014-02-13 | Savira Pharmaceuticals Gmbh | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
CN102911124B (zh) * | 2012-10-25 | 2015-11-25 | 山东大学 | 羟基嘧啶酮类化合物及其制备方法与应用 |
AU2013340559B2 (en) | 2012-10-29 | 2018-03-15 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
WO2014099586A1 (en) | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
DK3608325T3 (da) | 2012-12-21 | 2022-08-22 | Gilead Sciences Inc | Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse |
WO2014172188A2 (en) | 2013-04-16 | 2014-10-23 | Merck Sharp & Dohme Corp. | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors |
SI2997033T1 (en) | 2013-05-17 | 2018-04-30 | Merck Sharp & Dohme Corp. | FUZYCLE TRICYCLE HETEROCYCLIC COMPOUNDS AS HIV INTEGRATED INHIBITORS |
EP3008044B1 (en) | 2013-06-13 | 2018-11-21 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
EP3019503B1 (en) | 2013-07-12 | 2017-09-06 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
NO2865735T3 (xx) | 2013-07-12 | 2018-07-21 | ||
EA030695B1 (ru) | 2013-09-27 | 2018-09-28 | Мерк Шарп И Доум Корп. | Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич |
US9815796B2 (en) | 2013-12-23 | 2017-11-14 | Merck Sharp & Dohme Corp. | Pyrimidone carboxamide compounds as PDE2 inhibitors |
US20170253585A1 (en) * | 2014-02-03 | 2017-09-07 | Mylan Laboratories Ltd. | Processes for the preparation of intermediates of raltegravir |
WO2015140765A1 (en) | 2014-03-21 | 2015-09-24 | Mylan Laboratories Ltd. | A premix of crystalline raltegravir potassium salt and a process for the preparation thereof |
NO2717902T3 (xx) | 2014-06-20 | 2018-06-23 | ||
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
US9353093B2 (en) | 2014-10-07 | 2016-05-31 | Allergan, Inc. | Indole-1-carboxamides as kinase inhibitors |
US10259778B2 (en) | 2014-11-10 | 2019-04-16 | Aurobindo Pharma Ltd | Process for the preparation of raltegravir |
TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
EP3285581B1 (en) | 2015-03-26 | 2021-08-11 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
SI3466490T1 (sl) | 2015-04-02 | 2020-12-31 | Gilead Sciences, Inc. | Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba |
WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
EP3313852B1 (en) | 2015-06-25 | 2021-01-20 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors |
WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
US10548910B2 (en) | 2015-11-17 | 2020-02-04 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors |
WO2017106071A1 (en) | 2015-12-15 | 2017-06-22 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors |
WO2017113288A1 (en) | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
EP3472134B1 (en) | 2016-06-21 | 2021-10-20 | Pharmathen S.A. | Process for preparing compounds useful as intermediates for the preparation of raltegravir |
WO2018051239A1 (en) | 2016-09-15 | 2018-03-22 | Lupin Limited | Process for the preparation of pure and stable crystalline raltegravir potassium form 3 |
JP2020500866A (ja) | 2016-12-02 | 2020-01-16 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Hivインテグラーゼ阻害剤として有用な三環式複素環化合物 |
JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
WO2018140368A1 (en) | 2017-01-26 | 2018-08-02 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
CA3080012A1 (en) | 2017-11-14 | 2019-05-23 | Cambrex Profarmaco Milano S.R.L. | Process for the preparation of raltegravir |
AU2020316056A1 (en) * | 2019-07-23 | 2022-02-03 | Constellation Pharmaceuticals, Inc. | Modulators of TREX1 |
WO2021148992A1 (en) | 2020-01-23 | 2021-07-29 | Lupin Limited | Pharmaceutical compositions of raltegravir |
WO2021165927A1 (en) * | 2020-02-21 | 2021-08-26 | Wockhardt Bio Ag | 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT82199B (pt) | 1985-03-16 | 1990-11-07 | Wellcome Found | Processo para a preparacao de nucleosidos antivirais e de composicoes farmaceuticas que os contem |
US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US5637618A (en) * | 1990-06-01 | 1997-06-10 | Bioresearch, Inc. | Specific eatable taste modifiers |
DE4029654A1 (de) | 1990-09-19 | 1992-04-02 | Hoechst Ag | 2-phenyl-pyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
US5519021A (en) | 1992-08-07 | 1996-05-21 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
TW287160B (xx) | 1992-12-10 | 1996-10-01 | Hoffmann La Roche | |
US5919776A (en) * | 1996-12-20 | 1999-07-06 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
EP1069111A4 (en) * | 1998-03-26 | 2001-06-06 | Shionogi & Co | INDOLE DERIVATIVES EXER ANT ANTIVIRAL ACTIVITY |
CA2333707A1 (en) | 1998-06-03 | 1999-12-09 | Melissa Egbertson | Hiv integrase inhibitors |
US6306891B1 (en) * | 1998-06-03 | 2001-10-23 | Merck & Co., Inc. | HIV integrase inhibitors |
CA2333771A1 (en) | 1998-06-03 | 1999-12-09 | Mark W. Embrey | Hiv integrase inhibitors |
NZ509748A (en) | 1998-08-20 | 2003-01-31 | Toyama Chemical Co Ltd | Nitrogenous heterocyclic carboxamide derivatives or salts useful as antiviral agents |
KR20010089708A (ko) * | 1998-12-25 | 2001-10-08 | 시오노 요시히코 | Hiv 인테그라제 저해 활성을 갖는 방향족 복소환 유도체 |
JP2002538144A (ja) | 1999-03-04 | 2002-11-12 | コリア・リサーチ・インスティテュート・オブ・ケミカル・テクノロジー | 抗ウイルス性2,4−ピリミジンジオン誘導体およびその製造方法 |
JP2003503386A (ja) | 1999-06-25 | 2003-01-28 | メルク エンド カムパニー インコーポレーテッド | 1−(芳香族またはヘテロ芳香族置換)−3−(ヘテロ芳香族置換)−1,3−プロパンジオン類およびそれの使用 |
AU783981C (en) * | 2000-05-08 | 2007-05-03 | Janssen Pharmaceutica N.V. | HIV replication inhibitors |
GB0017676D0 (en) * | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
US20050010048A1 (en) | 2000-10-12 | 2005-01-13 | Linghang Zhuang | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors |
JP4287649B2 (ja) | 2000-10-12 | 2009-07-01 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類 |
ATE345129T1 (de) | 2000-10-12 | 2006-12-15 | Merck & Co Inc | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
CZ20031028A3 (cs) * | 2000-10-12 | 2003-08-13 | Merck & Co., Inc. | Aza- a polyazanaftalenylkarboxamidy |
DE60229364D1 (de) * | 2001-03-01 | 2008-11-27 | Shionogi & Co | Stickstoffhaltige heteroarylverbindungen mit hiv-integrase inhibierender wirkung |
US20040229909A1 (en) | 2001-08-10 | 2004-11-18 | Ryuichi Kiyama | Antiviral agent |
JP3927175B2 (ja) * | 2001-10-26 | 2007-06-06 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | N−置換ヒドロキシピリミジノンカルボキサミド系hivインテグラーゼ阻害薬 |
CA2463975A1 (en) | 2001-10-26 | 2003-05-01 | Maria Emilia Di Francesco | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
AU2002349675A1 (en) | 2001-12-05 | 2003-06-17 | Shionogi And Co., Ltd. | Derivative having hiv integrase inhibitory activity |
WO2004004657A2 (en) | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
MY136173A (en) | 2002-11-20 | 2008-08-29 | Japan Tobacco Inc | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
WO2004062613A2 (en) | 2003-01-13 | 2004-07-29 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
US7037908B2 (en) | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
-
2002
- 2002-10-21 JP JP2003537644A patent/JP3927175B2/ja not_active Expired - Lifetime
- 2002-10-21 HU HU0401740A patent/HU230248B1/hu active Protection Beyond IP Right Term
- 2002-10-21 KR KR1020047006234A patent/KR100862879B1/ko active IP Right Grant
- 2002-10-21 UA UA20040503960A patent/UA77454C2/uk unknown
- 2002-10-21 MX MXPA04003932A patent/MXPA04003932A/es active IP Right Grant
- 2002-10-21 CN CN028257650A patent/CN1700918B/zh not_active Expired - Lifetime
- 2002-10-21 PT PT02801950T patent/PT1441735E/pt unknown
- 2002-10-21 BR BRPI0213522A patent/BRPI0213522C1/pt not_active IP Right Cessation
- 2002-10-21 US US10/493,280 patent/US7169780B2/en not_active Expired - Lifetime
- 2002-10-21 DE DE122009000048C patent/DE122009000048I1/de active Pending
- 2002-10-21 EA EA200400585A patent/EA007060B1/ru active Protection Beyond IP Right Term
- 2002-10-21 CN CN2011100924805A patent/CN102219750B/zh not_active Expired - Lifetime
- 2002-10-21 GE GE5592A patent/GEP20063848B/en unknown
- 2002-10-21 CA CA002463976A patent/CA2463976C/en not_active Expired - Lifetime
- 2002-10-21 PL PL369223A patent/PL212914B1/pl unknown
- 2002-10-21 ES ES02801950T patent/ES2258668T3/es not_active Expired - Lifetime
- 2002-10-21 DK DK02801950T patent/DK1441735T3/da active
- 2002-10-21 EP EP02801950A patent/EP1441735B1/en not_active Expired - Lifetime
- 2002-10-21 ME MEP-2008-637A patent/ME00427B/me unknown
- 2002-10-21 DE DE60209381T patent/DE60209381T2/de not_active Expired - Lifetime
- 2002-10-21 IL IL16133702A patent/IL161337A0/xx unknown
- 2002-10-21 WO PCT/GB2002/004753 patent/WO2003035077A1/en active IP Right Grant
- 2002-10-21 RS YUP-356/04A patent/RS51542B/sr unknown
- 2002-10-21 DE DE200812000016 patent/DE122008000016I1/de active Pending
- 2002-10-21 CN CN201110092477.3A patent/CN102229605B/zh not_active Expired - Lifetime
- 2002-10-21 NZ NZ533057A patent/NZ533057A/en not_active IP Right Cessation
- 2002-10-21 AT AT02801950T patent/ATE318140T1/de active
- 2002-10-21 SI SI200230296T patent/SI1441735T1/sl unknown
-
2004
- 2004-04-07 IS IS7213A patent/IS2436B/is unknown
- 2004-04-09 IL IL161337A patent/IL161337A/en active IP Right Grant
- 2004-04-13 ZA ZA2004/02796A patent/ZA200402796B/en unknown
- 2004-04-21 CO CO04036632A patent/CO5580777A2/es active IP Right Grant
- 2004-04-26 HR HRP20040373AA patent/HRP20040373B1/xx not_active IP Right Cessation
- 2004-05-25 NO NO20042165A patent/NO325206B1/no not_active IP Right Cessation
-
2006
- 2006-05-16 HK HK06105678.2A patent/HK1085665A1/xx not_active IP Right Cessation
- 2006-07-24 US US11/491,815 patent/US7217713B2/en not_active Expired - Lifetime
- 2006-12-19 US US11/641,508 patent/US7435734B2/en not_active Expired - Lifetime
-
2008
- 2008-03-31 NL NL300340C patent/NL300340I2/nl unknown
- 2008-04-08 LU LU91428C patent/LU91428I2/fr unknown
- 2008-04-11 CY CY200800008C patent/CY2008008I1/el unknown
- 2008-04-18 LT LTPA2008007C patent/LTC1441735I2/lt unknown
- 2008-06-06 NO NO2008007C patent/NO2008007I1/no not_active IP Right Cessation
- 2008-06-17 FR FR08C0026C patent/FR08C0026I2/fr active Active
- 2008-06-20 US US12/214,595 patent/US7820660B2/en not_active Expired - Lifetime
-
2010
- 2010-09-17 US US12/884,734 patent/US20110034449A1/en not_active Abandoned
-
2016
- 2016-04-07 HU HUS1600016C patent/HUS1600016I1/hu unknown
-
2020
- 2020-08-10 NO NO2020026C patent/NO2020026I1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2020026I1 (no) | Raltegravir eller et farmasøytisk akseptabelt salt derav, spesielt kaliumsaltet | |
DK1441734T3 (da) | Dihydroxypyrimidin-carboxamid-inhibitorer a HIV-integrase | |
WO2004024078A3 (en) | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors | |
DE60315796D1 (de) | Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen | |
ATE364385T1 (de) | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer | |
ATE345129T1 (de) | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer | |
WO2005086700A3 (en) | Hiv integrase inhibitors | |
WO2005110414A3 (en) | Hiv integrase inhibitors | |
DE60323743D1 (en) | N-(substituierte benzyl)-8-hydroxy-1,6-naphthyridin-7- carbonsäureamide als hiv-integrase-hemmer | |
DE60322919D1 (de) | 8-hydroxy-1-oxotetrahydropyrrolopyrazinverbindungen, die sich als inhibitoren von hiv-integrase eignen | |
TW200640460A (en) | HIV integrase inhibitors |